marketcaparena
Search

    BIIB

    BIOGEN INC.

    Company overview

    Market capitalization
    $33.79B
    Employees
    7,500
    Latest publication
    2026-09-29
    About BIOGEN INC.

    Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue2,736,000,000USD2,477,800,000USD2,454,800,000USD2,645,500,000USD2,431,000,000USD2,454,700,000USD2,465,800,000USD2,464,900,000USD
    Cost Of Revenue776,900,000USD661,000,000USD876,600,000USD946,200,000USD577,900,000USD583,500,000USD638,700,000USD955,800,000USD
    Gross Profit1,959,100,000USD1,816,800,000USD1,578,200,000USD1,699,300,000USD1,853,100,000USD1,871,200,000USD1,827,100,000USD1,509,100,000USD
    Research Development529,600,000USD573,000,000USD369,600,000USD529,900,000USD545,900,000USD683,500,000USD673,000,000USD592,300,000USD
    Selling General Administrative709,700,000USD607,300,000USD594,800,000USD583,800,000USD572,500,000USD611,900,000USD588,400,000USD553,800,000USD
    Total Operating Expenses1,239,300,000USD1,419,400,000USD964,400,000USD1,111,200,000USD1,120,500,000USD1,362,200,000USD1,249,900,000USD1,142,600,000USD
    Operating Income719,800,000USD397,400,000USD613,800,000USD588,100,000USD732,600,000USD509,000,000USD577,200,000USD366,500,000USD
    Total Other Income Expense Net-587,400,000USD-19,700,000USD-56,500,000USD155,900,000USD-421,400,000USD-217,500,000USD-126,200,000USD332,200,000USD
    Interest Income25,300,000USD37,900,000USD31,600,000USD32,300,000USD23,900,000USD18,500,000USD11,600,000USD20,100,000USD
    Interest Expense82,300,000USD67,600,000USD67,400,000USD72,600,000USD60,000,000USD60,000,000USD59,800,000USD61,300,000USD
    Litigation Settlement Expense-400,000USD———————
    Income Before Tax132,400,000USD377,700,000USD557,300,000USD744,000,000USD311,200,000USD291,500,000USD451,000,000USD698,700,000USD
    Income Tax Expense34,900,000USD58,200,000USD90,800,000USD109,200,000USD70,700,000USD24,800,000USD62,500,000USD115,100,000USD
    Net Income97,500,000USD319,500,000USD466,500,000USD634,800,000USD240,500,000USD266,700,000USD388,500,000USD583,600,000USD
    Unclassified Operating Expenses—239,100,000USD——————
    Net Interest Income—-29,700,000USD-35,800,000USD-40,300,000USD-36,100,000USD-41,500,000USD-48,200,000USD-41,200,000USD
    Tax Provision—58,200,000USD90,800,000USD109,200,000USD70,700,000USD24,800,000USD62,500,000USD115,100,000USD
    Net Income From Continuing Ops—319,500,000USD466,500,000USD634,800,000USD240,500,000USD266,700,000USD388,500,000USD583,600,000USD
    Ebit—417,100,000USD624,700,000USD915,600,000USD681,900,000USD507,700,000USD531,600,000USD809,500,000USD
    Ebitda—553,600,000USD826,900,000USD1,109,900,000USD865,100,000USD691,700,000USD714,400,000USD968,400,000USD
    Depreciation And Amortization—136,500,000USD202,200,000USD194,300,000USD183,200,000USD184,000,000USD182,800,000USD158,900,000USD
    Reconciled Depreciation—204,400,000USD202,200,000USD194,300,000USD183,200,000USD184,000,000USD182,800,000USD158,900,000USD
    Selling And Marketing Expenses—————66,800,000USD——
    Minority Interest—————0USD0USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20162016-12-31 · USDFY 20142014-12-31 · USDFY 20132013-12-31 · USD
    Total Revenue9,810,600,000USD9,675,900,000USD9,835,600,000USD14,377,900,000USD13,452,900,000USD11,448,800,000USD9,703,300,000USD6,932,200,000USD
    Cost Of Revenue2,897,000,000USD2,310,400,000USD2,533,400,000USD1,955,400,000USD1,816,300,000USD1,433,200,000USD1,171,000,000USD857,700,000USD
    Gross Profit6,913,600,000USD7,365,500,000USD7,302,200,000USD12,422,500,000USD11,636,600,000USD10,015,600,000USD8,532,299,999USD6,074,500,000USD
    Research Development1,954,700,000USD2,488,500,000USD2,702,600,000USD2,770,500,000USD2,709,700,000USD1,973,300,000USD1,893,400,000USD1,455,800,000USD
    Selling General Administrative2,433,700,000USD2,319,900,000USD2,430,900,000USD2,279,700,000USD2,018,900,000USD1,843,600,000USD2,139,400,000USD1,639,400,000USD
    Unclassified Operating Expenses647,700,000USD——250,500,000USD929,200,000USD940,700,000USD434,200,000USD391,100,000USD
    Total Operating Expenses5,036,100,000USD4,875,200,000USD5,204,900,000USD5,379,900,000USD5,748,000,000USD4,863,900,000USD4,559,900,000USD3,559,000,000USD
    Operating Income1,877,500,000USD2,490,300,000USD2,097,300,000USD7,042,600,000USD5,888,600,000USD5,151,700,000USD3,972,400,000USD2,515,500,000USD
    Interest Income125,000,000USD67,600,000USD276,500,000USD120,000,000USD112,500,000USD63,400,000USD——
    Interest Expense246,000,000USD250,300,000USD246,900,000USD187,400,000USD200,600,000USD260,000,000USD29,500,000USD31,900,000USD
    Net Interest Income-142,500,000USD-182,700,000USD29,600,000USD-67,400,000USD-88,100,000USD-196,600,000USD——
    Income Before Tax1,401,500,000USD1,906,000,000USD1,296,800,000USD7,046,500,000USD5,899,600,000USD4,933,000,000USD3,931,500,000USD2,463,300,000USD
    Income Tax Expense108,111,000USD273,800,000USD135,300,000USD1,158,000,000USD1,425,600,000USD1,237,300,000USD989,900,000USD601,000,000USD
    Tax Provision263,600,000USD273,800,000USD135,300,000USD1,158,000,000USD1,425,600,000USD1,237,300,000USD——
    Net Income1,293,389,000USD1,632,200,000USD1,161,100,000USD5,888,500,000USD4,430,700,000USD3,702,800,000USD2,934,800,000USD1,862,300,000USD
    Net Income From Continuing Ops1,292,900,000USD1,632,200,000USD1,161,500,000USD5,967,900,000USD4,474,000,000USD3,695,700,000USD2,956,691,000USD1,879,565,000USD
    Ebit2,165,200,000USD2,322,500,000USD1,882,200,000USD7,275,200,000USD6,364,100,000USD5,708,800,000USD3,967,700,000USD2,490,000,000USD
    Ebitda3,100,600,000USD2,995,700,000USD2,377,000,000USD7,739,900,000USD7,014,600,000USD6,346,000,000USD4,604,900,000USD3,021,700,000USD
    Depreciation And Amortization935,400,000USD673,200,000USD494,800,000USD464,700,000USD650,500,000USD637,200,000USD637,200,000USD531,700,000USD
    Reconciled Depreciation779,900,000USD673,200,000USD494,800,000USD680,600,000USD1,016,600,000USD———
    Total Other Income Expense Net-476,000,000USD-584,300,000USD-800,500,000USD3,900,000USD11,000,000USD-218,700,000USD-40,900,000USD-52,200,000USD
    Minority Interest0USD0USD-400,000USD-4,100,000USD43,300,000USD-7,100,000USD6,781,000USD—
    Selling And Marketing Expenses—66,800,000USD71,400,000USD79,200,000USD90,200,000USD106,300,000USD92,900,000USD72,700,000USD
    Non Operating Income Net Other———3,900,000USD11,000,000USD-217,400,000USD-40,907,000USD-52,154,000USD
    Net Income Applicable To Common Shares———5,888,500,000USD4,430,700,000USD3,702,800,000USD2,934,784,000USD1,862,341,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets32,086,600,000USD29,483,100,000USD29,439,500,000USD29,207,500,000USD28,330,200,000USD28,033,100,000USD28,049,300,000USD28,313,200,000USD
    Short Term Investments184,000,000USD900,000,000USD807,200,000USD97,600,000USD——0USD—
    Total Current Assets7,305,700,000USD9,190,400,000USD8,974,100,000USD8,936,600,000USD7,967,700,000USD7,626,000,000USD7,456,800,000USD6,830,500,000USD
    Other Current Assets1,238,000,000USD1,168,300,000USD1,123,300,000USD916,800,000USD850,600,000USD757,300,000USD752,500,000USD674,000,000USD
    Other Non Current Assets831,800,000USD———————
    Total Liabilities13,238,600,000USD———————
    Total Current Liabilities3,917,100,000USD2,998,900,000USD3,349,400,000USD3,290,000,000USD3,183,700,000USD5,297,400,000USD5,528,800,000USD5,425,000,000USD
    Other Current Liabilities2,626,300,000USD———————
    Other Non Current Liabilities820,900,000USD———————
    Total Equity Including Noncontrolling Interest18,848,000,000USD———————
    Inventory2,384,300,000USD1,949,000,000USD2,168,100,000USD2,209,400,000USD2,274,300,000USD2,273,900,000USD2,460,500,000USD2,469,200,000USD
    Property Plant Equipment Net3,239,800,000USD3,269,200,000USD3,320,800,000USD3,406,200,000USD3,433,300,000USD3,478,800,000USD3,537,700,000USD3,591,300,000USD
    Goodwill6,990,800,000USD———————
    Intangible Assets13,516,400,000USD9,053,500,000USD9,178,500,000USD9,331,900,000USD9,467,500,000USD9,584,600,000USD9,691,200,000USD9,805,500,000USD
    Accounts Payable403,900,000USD358,500,000USD432,000,000USD413,100,000USD408,400,000USD391,500,000USD424,200,000USD422,700,000USD
    Common Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Retained Earnings20,969,700,000USD20,872,200,000USD20,552,700,000USD20,601,600,000USD20,135,100,000USD19,500,300,000USD19,259,800,000USD18,993,100,000USD
    Accumulated Other Comprehensive Income-127,700,000USD-140,200,000USD-182,000,000USD-214,800,000USD-238,100,000USD-174,500,000USD-136,200,000USD-145,700,000USD
    Cash And Equivalents1,285,000,000USD———————
    Total Stockholder Equity18,848,000,000USD18,651,700,000USD18,256,800,000USD18,207,500,000USD17,634,000,000USD16,978,700,000USD16,716,000,000USD16,358,900,000USD
    Total Liab—10,831,400,000USD11,182,700,000USD11,000,000,000USD10,696,200,000USD11,054,400,000USD11,333,300,000USD11,954,300,000USD
    Other Current Liab—2,546,800,000USD2,722,200,000USD2,773,600,000USD2,660,500,000USD2,530,700,000USD2,807,700,000USD2,755,100,000USD
    Capital Stock—100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Good Will—6,488,700,000USD6,491,100,000USD6,490,700,000USD6,493,100,000USD6,477,100,000USD6,478,900,000USD6,485,800,000USD
    Cash—3,382,700,000USD3,008,500,000USD3,862,800,000USD2,758,800,000USD2,598,300,000USD2,375,000,000USD1,699,200,000USD
    Cash And Short Term Investments—4,282,700,000USD3,815,700,000USD3,960,400,000USD2,758,800,000USD2,598,300,000USD2,375,000,000USD1,699,200,000USD
    Net Debt—3,179,200,000USD3,939,500,000USD2,727,300,000USD3,835,800,000USD4,022,900,000USD4,255,300,000USD4,951,700,000USD
    Short Long Term Debt Total—6,561,900,000USD6,948,000,000USD6,590,100,000USD6,594,600,000USD6,621,200,000USD6,630,300,000USD6,650,900,000USD
    Long Term Debt—6,288,500,000USD6,286,800,000USD6,285,100,000USD6,283,700,000USD4,548,700,000USD4,547,200,000USD4,545,800,000USD
    Long Term Investments—465,600,000USD431,900,000USD———0USD—
    Net Receivables—1,790,400,000USD1,867,000,000USD1,850,000,000USD2,084,000,000USD1,996,500,000USD1,868,800,000USD1,988,100,000USD
    Property Plant Equipment Gross—3,269,200,000USD6,252,000,000USD6,274,600,000USD6,242,000,000USD6,221,700,000USD6,208,500,000USD6,195,700,000USD
    Common Stock Shares Outstanding—148,400,000shares146,700,000shares147,100,000shares145,900,000shares145,900,000shares146,100,000shares145,900,000shares
    Non Current Assets Total—20,292,700,000USD20,465,400,000USD20,270,900,000USD20,362,500,000USD20,407,100,000USD20,592,500,000USD21,482,700,000USD
    Non Current Liabilities Total—7,832,500,000USD7,833,300,000USD7,710,000,000USD7,512,500,000USD5,757,000,000USD5,804,500,000USD6,529,300,000USD
    Non Current Liabilities Other—612,900,000USD748,500,000USD597,100,000USD634,500,000USD589,600,000USD732,300,000USD582,100,000USD
    Non Currrent Assets Other—777,500,000USD431,900,000USD562,600,000USD413,700,000USD373,100,000USD333,800,000USD278,100,000USD
    Net Working Capital—6,191,500,000USD5,624,700,000USD5,646,600,000USD4,784,000,000USD2,328,600,000USD1,928,000,000USD1,405,500,000USD
    Unclassified Non Current Assets—238,200,000USD611,200,000USD479,500,000USD554,900,000USD493,500,000USD550,900,000USD1,322,000,000USD
    Unclassified Current Liabilities—93,600,000USD114,800,000USD103,300,000USD114,800,000USD-1,123,000,000USD-1,200,300,000USD-1,249,000,000USD
    Unclassified Non Current Liabilities—931,100,000USD798,000,000USD827,800,000USD594,300,000USD618,700,000USD525,000,000USD1,401,400,000USD
    Unclassified Equity—-2,080,500,000USD-2,114,100,000USD-2,179,500,000USD-2,263,200,000USD-2,347,300,000USD-2,407,800,000USD-2,488,700,000USD
    Short Term Debt——80,400,000USD——1,749,100,000USD1,748,600,000USD1,748,100,000USD
    Short Long Term Debt—————1,749,100,000USD1,748,600,000USD1,748,100,000USD
    Current Deferred Revenue———————-1,748,100,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets29,439,500,000USD28,049,300,000USD26,844,800,000USD24,554,100,000USD23,877,300,000USD24,618,900,000USD27,234,300,000USD25,288,900,000USD
    Intangible Assets9,178,500,000USD9,691,200,000USD8,363,000,000USD1,850,100,000USD2,221,300,000USD3,084,300,000USD3,527,400,000USD3,120,000,000USD
    Other Current Assets1,123,300,000USD752,500,000USD1,182,000,000USD1,417,600,000USD740,800,000USD881,100,000USD631,000,000USD958,800,000USD
    Total Liab11,182,700,000USD11,333,300,000USD12,045,400,000USD11,165,700,000USD12,917,600,000USD13,932,800,000USD13,895,200,000USD12,257,300,000USD
    Total Stockholder Equity18,256,800,000USD16,716,000,000USD14,799,400,000USD13,397,900,000USD10,896,200,000USD10,700,300,000USD13,343,200,000USD13,039,600,000USD
    Other Current Liab2,722,200,000USD2,807,700,000USD2,623,600,000USD2,521,400,000USD2,535,200,000USD3,145,300,000USD2,765,800,000USD2,861,200,000USD
    Common Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Capital Stock100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD100,000USD
    Retained Earnings20,552,700,000USD19,259,800,000USD17,627,600,000USD16,466,500,000USD13,911,700,000USD13,976,300,000USD16,455,400,000USD16,257,000,000USD
    Good Will6,491,100,000USD6,478,900,000USD6,219,200,000USD5,749,000,000USD5,761,100,000USD5,762,100,000USD5,757,800,000USD5,706,400,000USD
    Cash3,008,500,000USD2,375,000,000USD1,049,900,000USD3,419,300,000USD2,261,400,000USD1,331,200,000USD2,913,700,000USD1,224,600,000USD
    Cash And Short Term Investments3,815,700,000USD2,375,000,000USD1,049,900,000USD4,892,800,000USD3,802,500,000USD2,610,100,000USD4,475,900,000USD3,538,000,000USD
    Total Current Assets8,974,100,000USD7,456,800,000USD6,859,300,000USD9,791,200,000USD7,856,500,000USD6,887,100,000USD8,381,800,000USD7,640,900,000USD
    Total Current Liabilities3,349,400,000USD5,528,800,000USD3,434,300,000USD3,272,800,000USD4,298,200,000USD3,742,200,000USD4,863,800,000USD3,295,200,000USD
    Net Debt3,939,500,000USD4,255,300,000USD6,288,300,000USD3,194,700,000USD5,342,100,000USD6,497,000,000USD3,453,800,000USD4,711,900,000USD
    Short Term Debt80,400,000USD1,748,600,000USD150,000,000USD194,400,000USD999,100,000USD166,400,000USD1,495,800,000USD—
    Short Long Term Debt Total6,948,000,000USD6,630,300,000USD7,338,200,000USD6,614,000,000USD7,603,500,000USD7,828,200,000USD6,367,500,000USD5,936,500,000USD
    Long Term Debt6,286,800,000USD4,547,200,000USD6,788,200,000USD6,281,000,000USD6,274,000,000USD7,426,200,000USD4,459,000,000USD5,936,500,000USD
    Long Term Investments431,900,000USD0USD0USD2,234,900,000USD892,000,000USD772,100,000USD1,408,100,000USD1,375,900,000USD
    Short Term Investments807,200,000USD0USD0USD1,473,500,000USD1,541,100,000USD1,278,900,000USD1,562,200,000USD2,313,400,000USD
    Net Receivables1,867,000,000USD1,868,800,000USD2,100,000,000USD2,136,400,000USD1,961,700,000USD2,327,300,000USD2,470,700,000USD2,485,400,000USD
    Inventory2,168,100,000USD2,460,500,000USD2,527,400,000USD1,344,400,000USD1,351,500,000USD1,068,600,000USD804,200,000USD929,900,000USD
    Accounts Payable432,000,000USD424,200,000USD403,300,000USD491,500,000USD589,200,000USD454,900,000USD530,800,000USD370,500,000USD
    Property Plant Equipment Net3,320,800,000USD3,537,700,000USD3,729,700,000USD3,702,500,000USD3,791,800,000USD3,844,800,000USD3,674,300,000USD3,601,200,000USD
    Property Plant Equipment Gross6,252,000,000USD6,208,500,000USD6,132,200,000USD3,702,500,000USD3,791,800,000USD3,844,800,000USD3,674,300,000USD3,601,200,000USD
    Accumulated Other Comprehensive Income-182,000,000USD-136,200,000USD-153,700,000USD-164,900,000USD-106,700,000USD-299,000,000USD-135,200,000USD-240,400,000USD
    Common Stock Shares Outstanding146,700,000shares145,900,000shares145,600,000shares146,000,000shares149,600,000shares161,300,000shares187,400,000shares205,300,000shares
    Non Current Assets Total20,465,400,000USD20,592,500,000USD19,985,500,000USD14,762,900,000USD16,020,800,000USD17,731,800,000USD18,852,500,000USD17,648,000,000USD
    Non Current Liabilities Total7,833,300,000USD5,804,500,000USD8,611,100,000USD7,892,900,000USD8,619,400,000USD10,190,600,000USD9,031,400,000USD8,962,100,000USD
    Non Current Liabilities Other748,500,000USD732,300,000USD781,100,000USD944,200,000USD1,650,900,000USD1,731,600,000USD1,761,600,000USD1,389,400,000USD
    Non Currrent Assets Other431,900,000USD333,800,000USD284,300,000USD1,529,200,000USD1,939,500,000USD2,899,000,000USD1,252,800,000USD1,690,600,000USD
    Net Working Capital5,624,700,000USD1,928,000,000USD3,425,000,000USD6,518,400,000USD3,558,300,000USD3,144,900,000USD3,518,000,000USD4,345,700,000USD
    Unclassified Non Current Assets611,200,000USD550,900,000USD1,389,300,000USD-1,955,700,000USD-1,939,500,000USD-2,826,500,000USD——
    Unclassified Current Liabilities114,800,000USD-1,200,300,000USD104,400,000USD65,500,000USD-824,400,000USD—-1,424,400,000USD63,500,000USD
    Unclassified Non Current Liabilities798,000,000USD525,000,000USD1,041,800,000USD-945,900,000USD-2,015,000,000USD-2,362,400,000USD-4,159,700,000USD-3,025,600,000USD
    Unclassified Equity-2,114,100,000USD-2,407,800,000USD-2,674,700,000USD—————
    Short Long Term Debt—1,748,600,000USD150,000,000USD—999,100,000USD—1,495,800,000USD—
    Current Deferred Revenue——3,000,000USD-97,200,000USD-589,200,000USD-83,200,000USD-530,800,000USD—
    Deferred Long Term Liab———334,700,000USD694,500,000USD1,032,800,000USD2,810,800,000USD1,636,200,000USD
    Other Liab———1,278,900,000USD2,015,000,000USD2,362,400,000USD4,159,700,000USD3,025,600,000USD
    Other Assets———1,652,900,000USD3,354,600,000USD4,196,000,000USD3,232,100,000USD2,160,500,000USD
    Treasury Stock———-2,977,100,000USD-2,977,100,000USD-2,977,100,000USD-2,977,100,000USD-2,977,100,000USD
    Net Tangible Assets———5,798,800,000USD2,913,800,000USD1,853,900,000USD4,058,000,000USD4,213,200,000USD
    Unclassified Current Assets———————-271,200,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation440,500,000USD
    Stock Based Compensation161,400,000USD
    Deferred Income Tax-4,000,000USD
    Other Non Cash Items-64,000,000USD
    Change To Inventory191,900,000USD
    Change To Liabilities-292,900,000USD
    Change In Working Capital224,100,000USD
    Operating Cash Flow1,094,400,000USD
    Capital Expenditures-92,100,000USD
    Net Investments3,384,200,000USD
    Other Investing Activities800,000USD
    Unclassified Investing Cash Flow-7,341,600,000USD
    Investing Cash Flow-4,048,700,000USD
    Net Debt Issuance1,303,300,000USD
    Net Common Stock Issuance-49,100,000USD
    Other Financing Activities-2,000,000USD
    Financing Cash Flow1,252,200,000USD
    Effect Of Forex Changes On Cash-21,400,000USD
    Change In Cash-1,723,500,000USD
    End Cash Flow1,285,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income319,500,000USD-48,900,000USD466,500,000USD634,800,000USD240,500,000USD266,700,000USD388,500,000USD583,600,000USD
    Depreciation204,400,000USD200,200,000USD202,200,000USD194,300,000USD183,200,000USD184,000,000USD182,800,000USD158,900,000USD
    Stock Based Compensation84,000,000USD59,600,000USD75,300,000USD74,900,000USD81,000,000USD75,100,000USD72,700,000USD70,600,000USD
    Other Non Cash Items141,900,000USD242,800,000USD100,500,000USD77,800,000USD115,900,000USD265,200,000USD110,400,000USD88,300,000USD
    Change To Account Receivables69,700,000USD-21,000,000USD229,400,000USD-55,700,000USD-110,600,000USD82,500,000USD114,500,000USD-87,200,000USD
    Change To Inventory116,200,000USD-29,400,000USD-7,400,000USD-89,900,000USD62,000,000USD-66,400,000USD-19,200,000USD-110,500,000USD
    Change In Working Capital-127,900,000USD-108,700,000USD174,200,000USD-789,600,000USD-333,500,000USD28,300,000USD233,800,000USD-188,600,000USD
    Total Cash From Operating Activities645,500,000USD511,900,000USD1,272,500,000USD160,900,000USD259,300,000USD760,900,000USD935,600,000USD625,800,000USD
    Capital Expenditures51,200,000USD43,900,000USD-46,200,000USD-16,600,000USD-47,100,000USD-66,300,000USD-130,000,000USD-42,600,000USD
    Free Cash Flow696,700,000USD555,900,000USD1,226,300,000USD144,300,000USD212,200,000USD694,600,000USD805,600,000USD583,200,000USD
    Investments-123,100,000USD-1,144,200,000USD-35,100,000USD-57,000,000USD-47,300,000USD-18,600,000USD-1,181,100,000USD466,500,000USD
    Total Cashflows From Investing Activities-209,500,000USD-1,231,700,000USD-35,100,000USD-57,000,000USD-47,300,000USD-18,600,000USD-1,181,100,000USD466,500,000USD
    Total Cash From Financing Activities-43,800,000USD-136,900,000USD-130,199,999USD-11,700,000USD-23,000,000USD7,900,000USD-6,600,000USD-245,200,000USD
    Change In Cash374,200,000USD-856,600,000USD1,104,000,000USD160,500,000USD223,300,000USD675,800,000USD-209,700,000USD834,500,000USD
    Begin Period Cash Flow3,008,500,000USD3,862,800,000USD2,758,800,000USD2,598,300,000USD2,375,000,000USD1,699,200,000USD1,908,900,000USD1,074,400,000USD
    End Period Cash Flow3,382,700,000USD3,008,500,000USD3,862,800,000USD2,758,800,000USD2,598,300,000USD2,375,000,000USD1,699,200,000USD1,908,900,000USD
    Other Cashflows From Investing Activities-35,200,000USD-1,275,600,000USD50,800,000USD-30,400,000USD-200,000USD88,300,000USD-1,100,000USD-2,600,000USD
    Other Cashflows From Financing Activities11,300,000USD-139,900,000USD-135,099,999USD-1,200,000USD1,300,000USD4,400,000USD-12,600,000USD-1,300,000USD
    Unclassified Operating Cash Flow23,600,000USD166,900,000USD253,800,000USD-31,300,000USD-27,800,000USD-58,400,000USD-52,600,000USD-87,000,000USD
    Unclassified Investing Cash Flow-102,400,000USD1,144,200,000USD-4,600,000USD47,000,000USD47,300,000USD-22,000,000USD131,100,000USD45,200,000USD
    Unclassified Financing Cash Flow-55,100,000USD3,000,000USD5,200,000USD6,100,000USD-24,300,000USD3,500,000USD15,300,000USD-253,200,000USD
    Net Borrowings—0USD-300,000USD-16,600,000USD0USD0USD0USD—
    Sale Purchase Of Stock——————-9,300,000USD9,300,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income1,292,900,000USD1,632,200,000USD1,161,500,000USD2,961,600,000USD1,727,600,000USD4,060,500,000USD5,888,500,000USD4,474,000,000USD
    Depreciation779,900,000USD673,200,000USD494,800,000USD518,400,000USD487,700,000USD457,200,000USD464,600,000USD650,500,000USD
    Stock Based Compensation290,800,000USD291,200,000USD264,200,000USD254,100,000USD238,600,000USD198,300,000USD182,300,000USD157,500,000USD
    Other Non Cash Items536,999,999USD592,200,000USD581,200,000USD-1,290,900,000USD1,758,300,000USD-448,000,000USD276,700,000USD397,200,000USD
    Change To Account Receivables42,100,000USD194,200,000USD56,700,000USD-222,400,000USD324,800,000USD2,800,000USD5,500,000USD-199,500,000USD
    Change To Inventory-64,700,000USD-273,800,000USD-130,900,000USD-320,200,000USD-462,400,000USD-316,300,000USD-19,200,000USD-52,100,000USD
    Change In Working Capital-1,057,599,999USD-155,200,000USD-648,700,000USD-890,300,000USD-145,500,000USD-187,200,000USD199,300,000USD400,200,000USD
    Total Cash From Operating Activities2,204,600,000USD2,875,500,000USD1,547,200,000USD1,384,300,000USD3,639,900,000USD4,229,800,000USD7,078,600,000USD6,187,700,000USD
    Capital Expenditures-153,800,000USD-359,800,000USD-311,400,000USD-240,300,000USD-294,900,000USD-551,800,000USD-514,500,000USD-770,600,000USD
    Free Cash Flow2,050,800,000USD2,515,700,000USD1,235,800,000USD1,144,000,000USD3,345,000,000USD3,678,000,000USD6,564,100,000USD5,301,600,000USD
    Investments-1,178,600,000USD-799,200,000USD-4,101,000,000USD1,576,600,000USD-309,800,000USD-29,900,000USD1,233,700,000USD339,400,000USD
    Total Cashflows From Investing Activities-1,371,100,000USD-799,200,000USD-4,088,700,000USD1,589,000,000USD-563,700,000USD-608,600,000USD470,500,000USD-2,046,300,000USD
    Net Borrowings-16,900,000USD-650,000,000USD187,300,000USD-1,002,200,000USD-170,000,000USD1,467,400,000USD1,467,400,000USD-3,200,000USD
    Total Cash From Financing Activities-301,900,000USD-683,500,000USD137,000,000USD-1,759,700,000USD-2,086,200,000USD-5,272,700,000USD-5,860,400,000USD-4,472,000,000USD
    Change In Cash633,500,000USD1,325,100,000USD-2,369,400,000USD1,157,900,000USD930,200,000USD-1,582,500,000USD1,689,100,000USD-349,200,000USD
    Begin Period Cash Flow2,375,000,000USD1,049,900,000USD3,419,300,000USD2,261,400,000USD1,331,200,000USD2,913,700,000USD1,224,600,000USD1,573,800,000USD
    End Period Cash Flow3,008,500,000USD2,375,000,000USD1,049,900,000USD3,419,300,000USD2,261,400,000USD1,331,200,000USD2,913,700,000USD1,224,600,000USD
    Other Cashflows From Investing Activities-38,700,000USD83,900,000USD-11,300,000USD24,400,000USD4,200,000USD-153,900,000USD-273,000,000USD-1,499,600,000USD
    Other Cashflows From Financing Activities-275,000,000USD-2,200,000USD-6,000,000USD-5,600,000USD-114,800,000USD2,915,600,000USD7,900,000USD-116,200,000USD
    Unclassified Operating Cash Flow361,600,000USD-158,100,000USD-305,800,000USD-168,600,000USD-426,800,000USD149,000,000USD—108,300,000USD
    Unclassified Financing Cash Flow-10,000,000USD-31,300,000USD-44,300,000USD——-2,972,000,000USD-1,467,400,000USD—
    Sale Purchase Of Stock—0USD0USD-750,000,000USD-1,800,000,000USD-6,679,100,000USD-5,868,300,000USD-4,352,600,000USD
    Unclassified Investing Cash Flow—275,900,000USD335,000,000USD228,300,000USD36,800,000USD127,000,000USD24,300,000USD-115,500,000USD
    Change To Liabilities———-347,700,000USD-9,100,000USD-50,400,000USD213,000,000USD770,900,000USD
    Cash And Cash Equivalents Changes———1,213,600,000USD990,000,000USD-1,651,500,000USD1,689,100,000USD-349,200,000USD
    Dividends Paid————-700,000USD-4,600,000USD—-36,400,000USD
    Exchange Rate Changes——————400,000USD-18,600,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q4 2020Quarterly · 2020-12-31ProductProduct2,301,600,000USD0000875045-21-000010
    Q4 2020Quarterly · 2020-12-31ProductProduct And Service Other132,000,000USD0000875045-21-000010
    Q4 2020Quarterly · 2020-12-31ProductRevenuesfromanticd20therapeuticprograms419,000,000USD0000875045-21-000010
    Q3 2020Quarterly · 2020-09-30ProductProduct2,690,300,000USD0000875045-21-000010
    Q3 2020Quarterly · 2020-09-30ProductProduct And Service Other125,700,000USD0000875045-21-000010
    Q3 2020Quarterly · 2020-09-30ProductRevenuesfromanticd20therapeuticprograms560,100,000USD0000875045-21-000010
    Q2 2020Quarterly · 2020-06-30ProductProduct2,795,700,000USD0000875045-21-000010
    Q2 2020Quarterly · 2020-06-30ProductProduct And Service Other407,600,000USD0000875045-21-000010
    Q2 2020Quarterly · 2020-06-30ProductRevenuesfromanticd20therapeuticprograms478,300,000USD0000875045-21-000010
    Q1 2020Quarterly · 2020-03-31ProductProduct2,904,600,000USD0000875045-21-000010
    Q1 2020Quarterly · 2020-03-31ProductProduct And Service Other109,300,000USD0000875045-21-000010
    Q1 2020Quarterly · 2020-03-31ProductRevenuesfromanticd20therapeuticprograms520,400,000USD0000875045-21-000010
    Q4 2019Quarterly · 2019-12-31ProductProduct2,924,800,000USD0000875045-21-000010
    Q4 2019Quarterly · 2019-12-31ProductProduct And Service Other145,700,000USD0000875045-21-000010
    Q4 2019Quarterly · 2019-12-31ProductRevenuesfromanticd20therapeuticprograms600,800,000USD0000875045-21-000010
    Q3 2019Quarterly · 2019-09-30ProductProduct2,894,700,000USD0000875045-21-000010
    Q3 2019Quarterly · 2019-09-30ProductProduct And Service Other109,600,000USD0000875045-21-000010
    Q3 2019Quarterly · 2019-09-30ProductRevenuesfromanticd20therapeuticprograms595,800,000USD0000875045-21-000010
    Q2 2019Quarterly · 2019-06-30ProductProduct2,880,300,000USD0000875045-21-000010
    Q2 2019Quarterly · 2019-06-30ProductProduct And Service Other160,000,000USD0000875045-21-000010
    Q2 2019Quarterly · 2019-06-30ProductRevenuesfromanticd20therapeuticprograms576,400,000USD0000875045-21-000010
    Q1 2019Quarterly · 2019-03-31ProductProduct2,680,000,000USD0000875045-21-000010
    Q1 2019Quarterly · 2019-03-31ProductProduct And Service Other292,400,000USD0000875045-21-000010
    Q1 2019Quarterly · 2019-03-31ProductRevenuesfromanticd20therapeuticprograms517,400,000USD0000875045-21-000010
    FY 2017Yearly · 2017-12-31GeographyGeographic Distribution Foreign52,700,000USD0000875045-19-000006
    FY 2017Yearly · 2017-12-31GeographyOther6,900,000USD0000875045-19-000006
    FY 2017Yearly · 2017-12-31GeographyUnited States-16,900,000USD0000875045-19-000006

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.